Seoul, South Korea

Eulsoon Park

This inventor holds 1 USPTO granted patent. Top assignee: Stemmedience Co., Ltd.. Active years: 2013.


Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Eulsoon Park: Innovator in Skin Condition Improvement

Introduction

Eulsoon Park is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of dermatology through his innovative research and development. His work focuses on improving skin conditions using advanced biological techniques.

Latest Patents

Eulsoon Park holds a patent for a composition aimed at improving skin conditions using fetal mesenchymal stem cells derived from amniotic fluid. The patent describes a culture medium for these stem cells, which serves as an active ingredient in the composition. The skin conditions targeted by this invention include whitening, wrinkles, skin damage caused by UV rays, and skin lifting. The method for preparing this composition involves culturing the fetal-derived mesenchymal stem cells in amniotic fluid and collecting the resulting culture medium. He has 1 patent to his name.

Career Highlights

Eulsoon Park is associated with Stemmedience Co., Ltd., where he continues to advance his research in regenerative medicine. His work has the potential to revolutionize treatments for various skin conditions, making significant strides in the field.

Collaborations

Eulsoon Park collaborates with esteemed colleagues, including Seungkwon You and Byung Sun Yoon. Their combined expertise enhances the research and development efforts at Stemmedience Co., Ltd.

Conclusion

Eulsoon Park is a pioneering inventor whose work in improving skin conditions through innovative compositions showcases the potential of stem cell technology. His contributions are paving the way for future advancements in dermatological treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…